Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure

2.50
Hdl Handle:
http://hdl.handle.net/10757/622259
Title:
Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure
Authors:
Nagarajan, Vijaiganesh; Hernandez, Adrian V. ( 0000-0002-9999-4003 ) ; Cauthen, Clay A.; Starling, Randall C.; Tang, W. H. Wilson
Citation:
Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure 2017, 183:35 American Heart Journal
Publisher:
Mosby Inc.
Journal:
American Heart Journal
Issue Date:
Jan-2017
URI:
http://hdl.handle.net/10757/622259
DOI:
10.1016/j.ahj.2016.09.008
Additional Links:
http://linkinghub.elsevier.com/retrieve/pii/S0002870316302046
Abstract:
Although heightened inflammation and autoimmune responses have been well described in patients with heart failure, the role of cell-mediated immune function in the pathogenesis and progression of heart failure is unclear. The aim of our study is to evaluate the prognostic role of cell-mediated immune function in patients with advanced heart failure. Methods We studied patients with advanced heart failure referred for evaluation of candidacy for advanced heart failure therapies between 2007 and 2010. Cell-mediated immune response was categorized into 3 groups—low or poor immune response (≤225 ng/mL), moderate or normal immune response (226-524 ng/mL), and strong immune response (≥525 ng/mL)—using a phytohemagglutinin-stimulated T-cell response assay. Results Out of 368 patients, 41 patients (11.1%) had poor immune function, 258 patients (70.1%) had normal immune function, and 69 patients (18.7%) had strong immune function. The primary outcome of all-cause mortality or cardiac transplantation occurred in 63.4%, 45.3%, and 34.8% in the poor immunity, normal immunity, and strong immune function groups, respectively. In univariate analysis, cell-mediated immune function was strongly associated with the primary outcome (P =.014). Poor immune function portended worse prognosis (hazard ratio = 2.18, 95% CI 1.01-4.70, P =.047), and strong immune function was associated with better survival (hazard ratio = 0.67, 95% CI 0.43-1.04). However, when adjusted for multiple variables in multivariate analysis, immune function status lost its overall significance to predict primary outcome (P = 0.11), but the direction to an increased risk of primary outcome was maintained in the poor immune function group. Conclusions Poor cell-mediated immune function measured by a clinically available assay could be associated with more adverse long-term prognosis in patients with advanced heart failure. © 2016 Elsevier Inc.
Type:
info:eu-repo/semantics/article
Rights:
info:eu-repo/semantics/restrictedAccess
Language:
eng
Description:
El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.
Keywords:
Acetylsalicylic acid; Angiotensin receptor antagonist; Beta adrenergic receptor blocking agent; Clopidogrel; Dipeptidyl carboxypeptidase inhibitor; Hydralazine; nitric acid derivative; Phytohemagglutinin; Spironolactone
ISSN:
00028703
Email:
tangw@ccf.org

Full metadata record

DC FieldValue Language
dc.contributor.authorNagarajan, Vijaiganeshes
dc.contributor.authorHernandez, Adrian V.es
dc.contributor.authorCauthen, Clay A.es
dc.contributor.authorStarling, Randall C.es
dc.contributor.authorTang, W. H. Wilsones
dc.date.accessioned2017-10-19T15:57:18Z-
dc.date.available2017-10-19T15:57:18Z-
dc.date.issued2017-01-
dc.identifier.citationUsefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure 2017, 183:35 American Heart Journales
dc.identifier.issn00028703-
dc.identifier.doi10.1016/j.ahj.2016.09.008-
dc.identifier.urihttp://hdl.handle.net/10757/622259-
dc.descriptionEl texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.es_PE
dc.description.abstractAlthough heightened inflammation and autoimmune responses have been well described in patients with heart failure, the role of cell-mediated immune function in the pathogenesis and progression of heart failure is unclear. The aim of our study is to evaluate the prognostic role of cell-mediated immune function in patients with advanced heart failure. Methods We studied patients with advanced heart failure referred for evaluation of candidacy for advanced heart failure therapies between 2007 and 2010. Cell-mediated immune response was categorized into 3 groups—low or poor immune response (≤225 ng/mL), moderate or normal immune response (226-524 ng/mL), and strong immune response (≥525 ng/mL)—using a phytohemagglutinin-stimulated T-cell response assay. Results Out of 368 patients, 41 patients (11.1%) had poor immune function, 258 patients (70.1%) had normal immune function, and 69 patients (18.7%) had strong immune function. The primary outcome of all-cause mortality or cardiac transplantation occurred in 63.4%, 45.3%, and 34.8% in the poor immunity, normal immunity, and strong immune function groups, respectively. In univariate analysis, cell-mediated immune function was strongly associated with the primary outcome (P =.014). Poor immune function portended worse prognosis (hazard ratio = 2.18, 95% CI 1.01-4.70, P =.047), and strong immune function was associated with better survival (hazard ratio = 0.67, 95% CI 0.43-1.04). However, when adjusted for multiple variables in multivariate analysis, immune function status lost its overall significance to predict primary outcome (P = 0.11), but the direction to an increased risk of primary outcome was maintained in the poor immune function group. Conclusions Poor cell-mediated immune function measured by a clinically available assay could be associated with more adverse long-term prognosis in patients with advanced heart failure. © 2016 Elsevier Inc.es
dc.formatapplication/pdfes
dc.language.isoenges
dc.publisherMosby Inc.es
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0002870316302046es
dc.rightsinfo:eu-repo/semantics/restrictedAccesses
dc.subjectAcetylsalicylic acides
dc.subjectAngiotensin receptor antagonistes
dc.subjectBeta adrenergic receptor blocking agentes
dc.subjectClopidogreles
dc.subjectDipeptidyl carboxypeptidase inhibitores
dc.subjectHydralazinees
dc.subjectnitric acid derivativees
dc.subjectPhytohemagglutinines
dc.subjectSpironolactonees
dc.titleUsefulness of cell-mediated immune function in risk stratification for patients with advanced heart failurees
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.journalAmerican Heart Journales
dc.description.peerreviewRevisión por pareses_PE
dc.contributor.emailtangw@ccf.orges_PE
All Items in UPC are protected by copyright, with all rights reserved, unless otherwise indicated.